S'abonner

Defining the Denominator for Measuring Quality of End-of-Life Care in Children with Cancer: Results of a Nominal Group Technique - 09/07/24

Doi : 10.1016/j.jpeds.2024.114038 
Emily E. Johnston, MD, MS 1, 2, , Raba Tefera, BA 1, Prasanna Ananth, MD, MPH 3, 4, Isaac Martinez, BA 1, Amy Porter, MD, PhD 5, Jennifer M. Snaman, MD, MS 5, Rachel Thienprayoon, MD, MS 6, 7, Steve Asch, MD, MPH 8, Smita Bhatia, MD, MPH 1, 2, Ronan O'Beirne, EdD 9
1 Institute for Cancer Outcomes and Survivorship, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 
2 Pediatric Hematology/Oncology, Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 
3 Department of Pediatrics, Yale School of Medicine, New Haven, CT 
4 Yale Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, New Haven, CT 
5 Department of Pediatrics, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, MA 
6 Division of Palliative Care, Department of Anesthesia, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 
7 Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 
8 Department of Medicine/Primary Care, School of Medicine, Stanford University, Stanford, CA 
9 Division of Continuing Medical Education, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 

Reprint requests: Emily E. Johnston, MD, MS, Institute for Cancer Outcomes and Survivorship, 1600 7th Avenue South, Lowder Suite 500, Birmingham, AL 35233.Institute for Cancer Outcomes and Survivorship1600 7th Avenue SouthLowder Suite 500BirminghamAL35233

Abstract

Objective

To determine which groups of children with cancer for whom to apply the newly developed quality measures (QMs) for end-of-life (EOL) care.

Study design

In a series of nominal groups, panelists answered the question: “Which children, diagnoses, conditions, or prognoses should be included when examining the quality of EOL care for children with cancer?” In each group, individual panelists proposed answers to the question. After collating individual responses, each panelist ranked their 5 top answers and points were assigned (5 pts for the best answer, 4 pts the second best, etc.). A team of pediatric oncology and palliative care clinician-scientists developed and applied a coding structure for responses and associated themes and subthemes for responses.

Results

We conducted 5 nominal groups with a total of 44 participants. Most participants identified as female (88%) and non-Hispanic White (86%). Seventy-nine percent were clinicians, mainly in pediatric palliative care, pediatric oncology, or hospice; 40% were researchers and 12% were bereaved parents. Responses fell into 5 themes: (1) poor prognosis cancer; (2) specific treatment scenarios; (3) certain populations; (4) certain symptoms; and (5) specific utilization scenarios. Poor prognosis cancer and specific treatment scenarios received the most points (320 pts [49%] and 147 pts [23%], respectively).

Conclusions

Participants developed a framework to identify which children should be included in EOL QMs for children with cancer. The deliberate identification of the denominator for pediatric QMs serves as a potent tool for enhancing quality, conducting research, and developing clinical programs.

Le texte complet de cet article est disponible en PDF.

Keywords : Nominal Group technique, pediatric palliative care, end-of-life care, pediatric oncology, quality measures

Abbreviations : BMT, GVHD, EOL, QMs, NGT, PPC, SME


Plan


 Previous Presentation: This work was presented as a poster at the American Society of Clinical Oncology Quality Symposium in October 2023, but has not otherwise been presented.


© 2024  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 271

Article 114038- août 2024 Retour au numéro
Article précédent Article précédent
  • Apnea, Intermittent Hypoxemia, and Bradycardia Events Predict Late-Onset Sepsis in Infants Born Extremely Preterm
  • Sherry L. Kausch, Douglas E. Lake, Juliann M. Di Fiore, Debra E. Weese-Mayer, Nelson Claure, Namasivayam Ambalavanan, Zachary A. Vesoulis, Karen D. Fairchild, Phyllis A. Dennery, Anna Maria Hibbs, Richard J. Martin, Premananda Indic, Colm P. Travers, Eduardo Bancalari, Aaron Hamvas, James S. Kemp, John L. Carroll, J. Randall Moorman, Brynne A. Sullivan, The Prematurity-Related Ventilatory Control (Pre-Vent) Investigators
| Article suivant Article suivant
  • Cerebral Palsy and Motor Impairment After Extreme Prematurity: Prediction of Diagnoses at Ages 2 and 10 Years
  • Timothy Marinelli, Joe X. Yi, T.Michael O'Shea, Robert M. Joseph, Stephen R. Hooper, Karl C.K. Kuban, Christina Sakai, Michael E. Msall, Rebecca Fry, Rachana Singh, ELGAN-ECHO Study Investigators, Julie V. Rollins, Bhavesh Shah, Linda Van Marter, Camilla Martin, Janice Ware, Caitlin Rollins, Cynthia Cole, Ellen Perrin, Christina Sakai, Frank Bednarek, Richard Ehrenkranz, Jennifer Benjamin, Angela Montgomery, T. Michael O'Shea, Lisa Washburn, Carl Bose, Diane Warner, Steve Engelke, Amanda Higginson, Jason Higginson, Kelly Bear, Mariel Poortenga, Steve Pastyrnak, Padu Karna, Nigel Paneth, Madeleine Lenski, Michael Schreiber, Scott Hunter, Deborah Klein, Maureen Pimental, Collen Hallisey, Taryn Coster, Maddie Dolins, Maggie Mittleman, Hannah Haile, Julia Rohde, Kaysi Herrera Pujols, Ellen Nylen, Emily Neger, Kathryn Mattern, Catherine Ma, Deanna Toner, Elizabeth Vitaro, Lauren Venuti, Beth Powers, Ann Foley, Taylor Merk, Joanne Williams, Elaine Romano, Christine Henry, Debbie Hiatt, Nancy Peters, Patricia Brown, Emily Ansusinha, Jazmyne James, Nou Yang, Gennie Bose, Janice Wereszczak, Janice Bernhardt, Joan Adams, Donna Wilson, Nancy Darden-Saad, Bree Williams, Emily Jones, Hannah Morris, Dinah Sutton, Julie Rathbun, Stephanie Fagerman, William Boshoven, Jalen Johnson, Brandon James, Cynthia Gile, Karen Miras, Carolyn Solomon, Deborah Weiland, Rugile Ramoskaite, Suzanne Wiggins, Krissy Washington, Ryan Martin, Barbara Prendergast, Emma Lynch, Sabina Hajdarovic, Beth Kring, Anne Smith, Susan McQuiston, Samantha Butler, Rachel Wilson, Kirsten McGhee, Patricia Lee, Aimee Asgarian, Anjali Sadhwani, Brandi Henson, Cecelia Keller, Jenifer Walkowiak, Susan Barron, Alice Miller, Brian Dessureau, Molly Wood, Jill Damon-Minow, Elaine Romano, Linda Mayes, Kathy Tsatsanis, Katarzyna Chawarska, Sophy Kim, Susan Dieterich, Karen Bearrs, Ellen Waldrep, Jackie Friedman, Gail Hounshell, Debbie Allred, Rebecca Helms, Lynn Whitley, Gary Stainback, Lisa Bostic, Amanda Jacobson, Joni McKeeman, Echo Meyer, Steve Pastyrnak, Joan Price, EdS; Megan Lloyd, Susan Plesha-Troyke, Megan Scott, Katherine M. Solomon, Kara Brooklier, Kelly Vogt

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.